commapot1
About
Long-term follow-up of CD19 chimeric antigen receptor T-cell treatments pertaining to relapsed/refractory serious lymphoblastic leukemia after allogeneic hematopoietic stem mobile or portable hair loss transplant.
Long-term follow-up of CD19 chimeric antigen receptor T-cell treatments pertaining to relapsed/refractory serious lymphoblastic leukemia after allogeneic hematopoietic stem mobile or portable hair loss transplant.